• 1
    Nakagawa F, Lodwick RK, Smith CJ et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012; 26: 335343.
  • 2
    Barbaro G, Klatt EC. Highly active antiretroviral therapy and cardiovascular complications in HIV-infected patients. Curr Pharm Des 2003; 9: 14751481.
  • 3
    Schambelan M, Benson CA, Carr A et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002; 31: 257275.
  • 4
    Orlando G, Meraviglia P, Cordier L et al. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med 2006; 7: 549557.
  • 5
    Guaraldi G, Zona S, Alexopoulos N et al. Coronary aging in HIV-infected patients. Clin Infect Dis 2009; 49: 17561762.
  • 6
    Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 25062512.
  • 7
    Fichtenbaum CJ. Metabolic abnormalities associated with HIV infection and antiretroviral therapy. Curr Infect Dis Rep 2009; 11: 8492.
  • 8
    Moyle G, Moutschen M, Martínez E et al. Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection. AIDS Rev 2010; 12: 314.
  • 9
    Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351: 18811883.
  • 10
    Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA, Weller IV. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 1999; 13: 735737.
  • 11
    Duprez DA, Neuhaus J, Kuller LH et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS ONE 2012; 7: e44454.
  • 12
    Obel N, Farkas DK, Kronborg G et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med 2010; 11: 130136.
  • 13
    Worm SW, Sabin C, Weber R et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201: 318330.
  • 14
    Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 24792486.
  • 15
    Durand M, Sheehy O, Baril J-G, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database. J Acquir Immune Defic Syndr 2011; 57: 245253.
  • 16
    Fichtenbaum CJ, Hadigan CM, Kotler DP et al. Treating morphologic and metabolic complications in HIV-infected patients on antiretroviral therapy. A consensus statement of an advisory committee of the International Association of Physicians in AIDS Care. IAPAC Mon 2005; 11: 3846.
  • 17
    Kalra S, Kalra B, Agrawal N, Unnikrishnan A. Understanding diabetes in patients with HIV/AIDS. Diabetol Metab Syndr 2011; 3: 2.
  • 18
    Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702710.
  • 19
    Iloeje UH, Yuan Y, L'italien G et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005; 6: 3744.
  • 20
    Lang S, Mary-Krause M, Cotte L et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170: 12281238.
  • 21
    Seden K, Merry C, Lamorde M et al. Prevalence and type of drug-drug interactions involving antiretrovirals in patients attending a specialist outpatient clinic in Kampala, Uganda. J Int AIDS Soc 2012; 15: 18335.
  • 22
    Marzolini C, Back D, Weber R et al. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 2011; 66: 21072111.
  • 23
    Gonzalez CJ, Rivera CA, Martin RJ, Mergian GA, Cruz H, Agins BD. Using computer-based monitoring and intervention to prevent harmful combinations of antiretroviral drugs in the New York State AIDS Drug Assistance Program. Jt Comm J Qual Patient Saf 2012; 38: 269276.
  • 24 [Internet]. [cited 2013 Jan 20]. Available at: (accessed 2 January 2013).
  • 25
    Onen NF, Overton ET, Seyfried W et al. Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials 2010; 11: 100109.
  • 26
    Zhou S-F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008; 9: 310322.
  • 27
    Boffito M, Acosta E, Burger D et al. Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antivir Ther (Lond) 2005; 10: 469477.
  • 28
    Fellay J, Marzolini C, Decosterd L et al. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol 2005; 60: 865873.
  • 29
    Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004; 57: 614.
  • 30
    Crawford KW, Spritzler J, Kalayjian RC et al. Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. AIDS Res Hum Retroviruses 2010; 26: 635643.
  • 31
    Waters L, Patterson B, Scourfield A et al. A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience. Int J STD AIDS 2012; 23: 546552.
  • 32
    Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP Jr. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med 2007; 167: 684691.
  • 33
    Smith C, Sabin CA, Lundgren JD et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24: 15371548.
  • 34
    Williams I, Churchill D, Anderson J et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012; 13 (Suppl 2): 185.
  • 35
    Du J, Wasserman BA, Tong W et al. Cholesterol is associated with the presence of a lipid core in carotid plaque of asymptomatic, young-to-middle-aged African Americans with and without HIV infection and cocaine use residing in inner-city Baltimore, Md., USA. Cerebrovasc Dis 2012; 33: 295301.
  • 36
    Cook JA, Burke-Miller JK, Cohen MH et al. Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS 2008; 22: 13551363.
  • 37
    Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001; 2: 105113.
  • 38
    Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS 1999; 13: 23112312.
  • 39
    Barzon L, Zamboni M, Pacenti M et al. Do oestrogen receptors play a role in the pathogenesis of HIV-associated lipodystrophy? AIDS 2005; 19: 531533.
  • 40
    Bonnet E, Genoux A, Bernard J, Fauvel J, Massip P, Perret B. Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy. Clin Chem Lab Med 2007; 45: 815821.
  • 41
    Sandler NG, Wand H, Roque A et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203: 780790.
  • 42
    Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22: F17F24.
  • 43
    Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis 2011; 53: 8491.
  • 44
    Ding X, Andraca-Carrera E, Cooper C et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr 2012; 61: 441447.
  • 45
    Holmberg SD, Moorman AC, Williamson JM et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360: 17471748.
  • 46
    Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30: 471477.
  • 47
    Moyle GJ, Andrade-Villanueva J, Girard P-M et al. A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity. Antivir Ther (Lond) 2012; 17: 689700.
  • 48
    Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002; 185: 456462.
  • 49
    El-Sadr WM, Lundgren JD, Neaton JD et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 22832296.
  • 50
    Woerle HJ, Mariuz PR, Meyer C et al. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 2003; 52: 918925.
  • 51
    Lee GA, Rao MN, Grunfeld C. The effects of HIV protease inhibitors on carbohydrate and lipid metabolism. Curr Infect Dis Rep 2004; 6: 471482.
  • 52
    Brown TT. Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort Study. Arch Intern Med 2005; 165: 11791184.
  • 53
    Miners JO. Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid. Clin Pharmacokinet 1989; 17: 327344.
  • 54
    Abobo CV, Xian Y. Lack of pharmacokinetic interaction between dipyridamole and zalcitabine in rats. Cell Mol Biol (Noisy-le-grand) 1997; 43: 10451050.
  • 55
    Janneh O, Jones E, Chandler B, Owen A, Khoo SH. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 2007; 60: 987993.
  • 56
    Farid NA, Payne CD, Small DS et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007; 81: 735741.
  • 57
    Collet J-P, Hulot J-S, Pena A et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309317.
  • 58
    Silverberg MJ, Leyden W, Hurley L et al. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med 2009; 150: 301313.
  • 59
    Townsend ML, Hollowell SB, Bhalodia J, Wilson KH, Kaye KS, Johnson MD. A comparison of the effectiveness of lipid-lowering therapy between HIV- and non-HIV-infected subjects with hyperlipidaemia. Int J STD AIDS 2007; 18: 851855.
  • 60
    Ganesan A, Crum-Cianflone N, Higgins J et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis 2011; 203: 756764.
  • 61
    Moore RD, Bartlett JG, Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS ONE 2011; 6: e21843.
  • 62
    Fichtenbaum CJ, Gerber JG, Rosenkranz SL et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS [Internet]. 2002;16 (4) Available at:
  • 63
    Samineni D, Desai PB, Sallans L, Fichtenbaum CJ. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. J Clin Pharmacol 2012; 52: 922931.
  • 64
    Van der Lee M, Sankatsing R, Schippers E et al. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther (Lond) 2007; 12: 11271132.
  • 65
    Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW. Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr 2008; 47: 570578.
  • 66
    Asboe D, Aitken C, Boffito M et al. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals. HIV Med 2011; 13: 144.
  • 67
    NORVIR (Ritonavir). Summary of product characteristics. 26 August 1996 (revised 17 January 2013). Abbott Laoratories Limited, Abbott House, Maidenhead, Berkshire.
  • 68
    REYATAZ (Atazanavir sulphate). Summary of product characterstics. 2 March 2004 (revised June 2013). Bristol-Squibb Pharmaceuticals Ltd, Bristol Squibb House, Uxbridge, Middlesex.
  • 69
    Abernethy DR, Gutkowska J, Lambert MD. Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics. J Cardiovasc Pharmacol 1988; 12 (Suppl 7): S67S71.
  • 70
    Abernethy DR. The pharmacokinetic profile of amlodipine. Am Heart J 1989; 118 (5 Pt 2): 11001103.
  • 71
    Glesby MJ, Aberg JA, Kendall MA et al. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther 2005; 78: 143153.
  • 72
    el-Makri A, Larabi MS, Kechrid C, Belkahia C, Ben Ayed H. Fatal bone-marrow suppression associated with captopril. Br Med J (Clin Res Ed) 1981; 283: 277278.
  • 73
    Moussa Z, Schiano T, Spatoliatore G, Salman S. Neutropenia induced by low-dose captopril. N Y State J Med 1992; 92: 219220.
  • 74
    Bourrié M, Meunier V, Berger Y, Fabre G. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. Drug Metab Dispos 1999; 27: 288296.
  • 75
    Hanatani T, Fukuda T, Ikeda M et al. CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro. Pharmacogenomics J 2001; 1: 288292.
  • 76
    De Wit S, Sabin CA, Weber R et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008; 31: 12241229.
  • 77
    Worth L, Elliott J, Anderson J, Sasadeusz J, Street A, Lewin S. A cautionary tale: fatal lactic acidosis complicating nucleoside analogue and metformin therapy. Clin Infect Dis 2003; 37: 315316.
  • 78
    Scheen AJ. Pharmacokinetic interactions with thiazolidinediones. Clin Pharmacokinet 2007; 46: 112.
  • 79
    Becker ML, Visser LE, Trienekens PH, Hofman A, van Schaik RHN, Stricker BHC. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther 2008; 83: 288292.
  • 80
    Boffito M, Maitland D, Samarasinghe Y, Pozniak A. The pharmacokinetics of HIV protease inhibitor combinations. Curr Opin Infect Dis 2005; 18: 17.